Showing posts with label Abductions UFOs and Nuclear Weapons. Show all posts
Showing posts with label Abductions UFOs and Nuclear Weapons. Show all posts

Friday, June 13, 2014

Warm or cold? Dinosaurs had 'in-between' blood

dinosaur-growth-rates
Comparative growth rates in vertebrates. Dinosau rs grew intermediate to endothermic mammals and birds and ectothermic reptiles and fi sh, but closest to living mesotherms.John Grady
Dinosaurs may not have been cold-blooded like modern reptiles or warm-blooded like mammals and birds instead, they may have dominated the planet for 135 million years with blood that ran neither hot nor cold, but was a kind of in-between that's rare nowadays, researchers say.
Modern reptiles such as lizards, snakes and turtles are cold-blooded or ectothermic, meaning their body temperatures depend on their environments. Birds and mammals, on the other hand, are warm-blooded, meaning they control their own body temperatures, attempting to keep them at a safe constant in the case of humans, at about 98.6 degrees Fahrenheit (37 degrees Celsius).
Dinosaurs are classified as reptiles, and so for many years scientists thought the beasts were cold-blooded, with slow metabolisms that forced them to lumber across the landscape. However, birds are modern-day dinosaurs and warm-blooded, with fast metabolic rates that give them active lifestyles, raising the question of whether or not their extinct dinosaur relatives were also warm-blooded. [Avian Ancestors: Dinosaurs That Learned to Fly (Images)]
Animal metabolism
To help solve this decades-old mystery, researchers developed a new method for analyzing the metabolism of extinct animals. They found "dinosaurs do not fit comfortably into either the cold-blooded or warm-blooded camp they genuinely explored a middle way," said lead study author John Grady, a theoretical ecologist at the University of New Mexico.
Scientists often seek to deduce the metabolisms of extinct animals by looking at the rates at which their bones grow. The method resembles cutting into a tree and looking at the thickness of the rings of wood within, which can reveal how well or poorly that tree grew any given year. Similarly, looking at the way bone is deposited in layers in fossils reveals how quickly or slowly that animal might have grown.
Grady and his colleagues not only looked at growth rings in fossils, but also sought to estimate their metabolic rates by looking at changes in body size as animals grew from birth to adults. The researchers looked at a broad spectrum of animals encompassing both extinct and living species, including cold- and warm-blooded creatures, as well as dinosaurs.
The scientists found growth rate to be a good indicator of metabolic rates in living animals, ranging from sharks to birds. In general, warm-blooded mammals that grow about 10 times faster than cold-blooded reptiles also metabolize about 10 times faster.
When the researchers examined how fast dinosaurs grew, they found that the animals resembled neither mammals nor modern reptiles, and were neither ectotherms nor endotherms. Instead, dinosaurs occupied a middle ground, making them so-called "mesotherms."
Modern mesotherms
Today, such energetically intermediate animals are uncommon, but they do exist. For instance, the great white shark, tuna and leatherback sea turtle are mesotherms, as is the echidna, an egg-laying mammal from Australia. Like mammals, mesotherms generate enough heat to keep their blood warmer than their environment, but like modern reptiles, they do not maintain a constant body temperature. [See Photos of Echidna and Other Bizarre Monotremes]
"For instance, tuna body temperature declines when they dive into deep, colder waters, but it always stays above the surrounding water," Grady told Live Science.
Body size may play a role in mesothermy, because larger animals can conserve heat more easily. "For instance, leatherback sea turtles are mesotherms, but smaller green sea turtles are not," Grady said. However, mesothermy does not depend just on large size. "Mako sharks are mesotherms, but whale sharks are regular ectotherms," Grady said.
Endotherms can boost their metabolisms to warm up "for instance, we shiver when cold, which generates heat," Grady said. "Mesotherms have adaptations to conserve heat, but they do not burn fat or shiver to warm up. Unlike us, they don't boost their metabolic rate to stay warm."
Some animals are what are known as gigantotherms, meaning they are just so massive that they maintain heat even though they do not actively control their body temperature.
"Gigantotherms like crocodiles rely on basking to heat up, so they are not mesotherms," Grady said. "Gigantotherms are slower to heat up and cool down, but if they rely on external heat sources like the sun, then they are not mesotherms. In general, mesotherms produce more heat than gigantotherms and have different mechanisms for conserving it."
Advantages of being a mesotherm
Mesothermy would have permitted dinosaurs to move, grow and reproduce faster than their cold-blooded reptilian relatives, making the dinosaurs more dangerous predators and more elusive prey. This may explain why dinosaurs dominated the world until their extinction about 65 million years ago, Grady suggested.
At the same time, dinosaurs' lower metabolic rates compared to mammals allowed them to get by on less food. This may have permitted the enormous bulk that many dinosaur species attained. "For instance, it is doubtful that a lion the size of T. rex would be able to eat enough wildebeests or elephants without starving to death," Grady said. "With their lower food demands, however, a real T. rex was able to get by just fine."
All in all, Grady suspected that where direct competition occurs, warm-blooded endotherms suppress mesotherms, mesotherms suppress active but cold-blooded ectotherms, and active ectotherms suppress more lethergic sit-and-wait ectotherms
Although mesothermy appears widespread among dinosaurs, not every dinosaur was necessarily a mesotherm, Grady said. "Dinosaurs were a big and diverse bunch, and some may have been endotherms or ectotherms," he said. "In particular, feathered dinosaurs are a bit of a mystery. What do you call a metabolically intermediate animal covered in feathers? Is it like the mesothermic echidna? Or just a low-power endotherm?"
The first bird, Archaeopteryx, "was more like a regular dinosaur than any living bird," Grady said. "It grew to maturity in about two years. In contrast, a similarly sized hawk grows in about six weeks, almost 20 times faster. Despite feathers and the ability to take flight, the first birds were not the active, hot-blooded fliers their descendants came to be."
These findings could help shed light on how warm-blooded animals such as humans evolved.
"The origins of endothermy in mammals and birds are unclear," Grady said. Studying the growth rates of the ancestors of birds and mammals "will shed light on these mysterious creatures."
The scientists detailed their findings in the June 13 issue of the journal Science.

Tuesday, February 18, 2014

Can 'Robotic' Pills Replace Injections?

Entrepreneur Mir Imran Hopes to Change Diabetes Treatment

Feb. 17, 2014 7:05 p.m. ET

The adage "Take two aspirin and call me in the morning" is destined for a futuristic makeover. Doctors may just as easily recommend swallowing sophisticated gadgets instead.
That is the hope of prolific inventor Mir Imran, who has created a robotic pill to replace injectable drugs for chronic conditions such as diabetes. The gadget, in preclinical studies and backed by Google Inc. GOOG +0.73% 's venture-capital unit, consists of an ingestible polymer and tiny hollow needles made of sugar that are designed to safely deliver drugs to the small intestine.
Such a pill would have seemed unthinkable years ago. But advancements in technology and scientific research have recently led to two federally approved robotic pills.
The Food and Drug Administration earlier this month cleared the PillCam, a pill-sized camera from Given Imaging Ltd. GIVN 0.00% that photographs human insides in a hunt for colon polyps. Another company, Proteus Digital Health Inc., received clearance a year and a half ago to put ingestible sensors inside pills to help patients and doctors determine how many they have taken.
Mr. Imran's pill hasn't yet been tested in humans, so it is probably still at least a year away from even seeking federal approval. It also would require substantial financing to manufacture millions of pills. But if it is successful, the gadget has the potential to disrupt a multibillion-dollar market for injectable drugs and make life easier for millions of sufferers of conditions such as diabetes and rheumatoid arthritis.
Mr. Imran is a safer bet than most entrepreneurs. The Indian-born founder of the research lab and business incubator InCube Labs in Silicon Valley has founded more than 20 medical-device startups, a dozen of which have been acquired by companies such as Medtronic Inc. MDT -1.03% He owns over 300 patents and helped develop the first implantable cardioverter defibrillator to correct irregular heartbeats.
Rani Therapeutics, the startup formed at InCube Labs to commercialize the robot pill, last year raised funds from Google Ventures and angel-investment fund VentureHealth.
Blake Byers, the Google Ventures general partner who spearheaded the investment, says Mr. Imran may be achieving one of the "holy grails" for biotechnology by figuring out how to deliver protein-based drugs such as basal insulin to the body without the use of a syringe.
"This investment is not exactly in our wheelhouse, but we're open to people who can change our minds," Mr. Byers said. "This one really stood out as a huge clinical need; $110 billion is spent in the U.S. every year on biologics, all of them injectable."
Drugs used to treat a variety of chronic conditions, including diabetes, rheumatoid arthritis, osteoporosis and multiple sclerosis, can't be delivered in pill form because stomach acids break down the proteins.
Mr. Imran's idea is an "autonomic robotic delivery system" that can stay intact in the stomach and small intestine long enough to deliver enough of the drug. The body's natural digestive processes activate the pill to perform a series of functions even without any electronics.
As the pH level, or acidity, builds up in the intestine, the outer layer of the polymer pill casing dissolves, exposing a tiny valve inside the device that separates two chemicals, citric acid and sodium bicarbonate.
When the valve becomes exposed, the chemicals mix together to create carbon dioxide. This acts as an energy source, gently inflating a balloon-like structure that is outfitted with needles made of sugar and preloaded with drugs.
The needles push into the intestinal wall, which has no pain receptors. Once lodged there, they detach from the gadget and slowly dissolve, while the balloon and polymer casing pass from the body.
In numerous attempts over the past 40 years to make insulin and other drugs available in pill form, pharmaceutical companies have been able to create coatings so tough that pills can reach the small intestine. But once there, they are attacked by enzymes, which has compromised the pills and prevented significant amounts of the drug from reaching the patient.
In preclinical studies, Rani Therapeutics has shown that its robotic pill can boost drug absorption at least as high as syringes can, Mr. Imran said.
"I am guardedly optimistic, and I say guardedly because there is still a lot of work left to do," said Elliott Sigal, who several months ago retired from drug maker Bristol-Myers Squibb Co. His 16-year run at the drug maker included top posts in drug discovery and development and a nearly 10-year tenure as the head of research and development.
"Rani's engineering-based approach to this is very innovative," said Mr. Sigal, who doesn't have a financial stake in the business. "He is getting results that I have not seen before. It hasn't been tried in human patients yet, and things do sometimes fail at that level. But if the [trials] data continues, there will be a great deal of pharma interest."
Mr. Imran said pharmaceutical companies, which would license the technology for use with their own drugs, have already expressed interest. He declined to give further details.
Rani Therapeutics will spend another year testing the robot pill, he said, in the hope that it will have definitive clinical data in 2015.
If the data back up his claim about the pill, it could not only help millions of patients ditch their syringes and stick-pens, but it could remove another barrier for a range of early-stage treatments that currently have no safe avenue into the body, said Google Ventures' Mr. Byers.

Sunday, December 15, 2013

Conflict Minerals, Rebels and Child Soldiers in Congo

T-80

http://lurch2.blogspot.com/2013/10/t-80.html

Fairchild Republic A-10 Thunderbolt II

http://lurch2.blogspot.com/2013/10/fairchild-republic-10-thunderbolt-ii.html

Fed keeps pumping to keep economy churning

http://lurch2.blogspot.com/2013/10/fed-keeps-pumping-to-keep-economy.html

DEMOCRATS TO AMERICA: WE OWN THE GOVERNMENT!

http://lurch2.blogspot.com/2013/10/democrats-to-america-we-own-government.html

Betty and Barney Hill collection

http://lurch2.blogspot.com/2013/08/betty-and-barney-hill-collection.html

Cold, Blue World: 'Small' Alien Planet Captured on Camera

http://lurch2.blogspot.com/2013/08/cold-blue-world-small-alien-planet.html

Potential cultural impact of extraterrestrial contact

http://lurch2.blogspot.com/2013/11/potential-cultural-impact-of.html

Nostradamus

http://lurch2.blogspot.com/2013/09/nostradamus.html

Intel 4004

http://lurch2.blogspot.com/2013/12/intel-4004.html

USS Zumwalt DDG 1000 Pics

http://lurch2.blogspot.com/2013/10/uss-zumwalt-ddg-1000-pics.html

The Cannibal Warlords of Liberia (Full Length Documentary)

http://lurch2.blogspot.com/2013/12/the-cannibal-warlords-of-liberia-full.html

Russia’s top secret bases

http://lurch2.blogspot.com/2013/07/russias-top-secret-bases.html

Saturday, December 14, 2013

The shadow genome: why DNA isn't destiny

Epigenetics is changing the way scientists look at genetic inheritance
via farm3.staticflickr.com
How does a mother’s weight-loss surgery affect her child’s risk of obesity? It’s a question scientists have been struggling with since a Laval University study published in April, which looked at children born to mothers who’d undergone gastric bypass surgery prior to their pregnancy. Researchers knew the children were less prone to obesity, but as they tried to figure out why, they found something unexpected. The children’s genes were different — not their genetic code itself, but the markers in between that code. It was a small study, but the results were striking: more than 5,000 genes were expressed differently when parents had undergone the surgery. The surgery had changed something in the mother’s DNA, and when the children were born just a few years later, it appeared to have changed in them too.
Passed from parent to child without ever touching the genetic code
The finding is part of a raft of studies looking at the phenomenon of epigenetic inheritance — how characteristics can be passed down from parent to child without ever touching the genetic code. Together, these studies are having a profound impact on how scientists look at biological inheritance and pointing the way towards new ways of thinking about our bodies, particularly for inherited factors like obesity or cancer risk. Instead of DNA's coded string of nucleotides (all those Gs, Ts, As and Cs you learned in school), this new kind of inheritance deals with methyl markers found between the nucleotides. Those markers change the way your body’s RNA reads the code, altering the proteins that come out of it. More importantly, the markers can be added and removed in response to external stimuli, making them a kind of running commentary in the margins of your DNA.
The events of your life leave a lasting mark on your biological makeup
The science behind this mechanism has been building steam for decades, but while we know certain experiences or drugs can add or remove markers, scientists are still learning how fluid the markers are. More recently, a growing number of researchers believe they're passed from parent to child as part of DNA transfer. On the face of it, it's a simple idea — why would the markers on DNA behave any differently from DNA itself? — but the implications could be enormous, rewriting century-old assumptions about the nature of biological inheritance. In this new paradigm, the events of your life leave a lasting mark on your biological makeup, changing not just your own life but the lives of your descendants. In the other direction, your own methyl markers work as a kind of ancestral memory, encoding experiences that reach back centuries and change within each lifetime. Instead of a permanent code, what if your body's data is written in pencil?
Lab rats conditioned to fear a smell will pass that fear onto their children
In practice, that has led to some surprising results, even beyond stories of transgenerational weight loss. A study from Emory this month found that lab rats conditioned to fear a certain smell will pass that fear on to their children. The shock? The inheritance happens biologically, even without behavioral contact. If the father runs from a certain smell, his pups will too, even if they don't know why. Human beings have exhibited similar behavior in earlier studies: children of PTSD sufferers, for instance, have been shown to have lower levels of stress-response hormones, possibly as a result of their parents’ trauma. But these experiments could always be explained away as more nurture than nature, the behavioral effects of growing up with a traumatized parent. Now, it's not so clear. What if those stressful experiences are leaving epigenetic markers, passed down from parent to child?
"It's an exciting time. We're shaking up fundamental theories."
It's entirely possible. Brian Dias, one of the researchers behind the recent mouse-fear study, thinks the field will have a particular impact on mental health treatments. "We're definitely going to see the field blossom with neuropsychiatric disorders," Dias says. "Depressive symptoms and stress biology are going to be really important." Modern treatments see depression and anxiety disorders as neurochemical problems, but they may come to be seen as epigenetic problems too. It’s a particularly crucial shift because your epigenome can be rewritten. Previous studies have used pharmaceuticals to remove methyl markers, and Dias says the next step for his research will be using those drugs — or other interventions — to target the effects themselves. Now that Dias has shown he can lay down fear markers, the challenge is figuring out a process that erases them. "It might be drugs, it might be diet, it might be exercise," he says. "We shouldn't shy away from these broad approaches."
Part of the reason he's staying so open is that, for the most part, we're still in the dark about what causes the markers to change. Moshe Szyf, a McGill professor who's been working on cancer-based epigenetics for decades, says the uncertainty is part of what makes the field so exciting. "We still don't really understand how experience can create these marks," Szyf says. "It's not so easy to find out. But we understand that there are changes." And judging by Dias' work, we're beginning to understand how to make those changes ourselves. The work on scent and anxiety is the beginning. If similar work on diet or maternal behavior pans out, it could be just as revolutionary. Szyf is optimistic, even if he doesn't expect to build a consensus for new inheritance theories overnight. "It's an exciting time. We're shaking up fundamental theories, and that's tough to do

 http://www.theverge.com/